Imagine this: someone you love has just heard the words “you have cancer.” They are meeting with their oncologist – perhaps even me, or one of my colleagues – and come to understand that there is ...

Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces ...

The weather caused the last work week of January to be short for legislators. This week’s episode covers a bill headed to the ...

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

BeiGene is back with a new partnership and oncology campaign to raise awareness about biomarker testing for patients with chronic lymphocytic leukemia (CLL), a blood cancer marked by the ...

Across all cancer types, less than 50% of patients underwent biomarker testing before first-line treatment. Many patients with advanced cancer do not receive guideline-recommended biomarker testing ...

Precision Care Companion (PCC) enhances biomarker testing and precision therapy adoption in community oncology, uniting practices, labs, and biopharma for improved patient outcomes. PCC focuses on ...

WEST VIRGINIA (WVNS) – A cancer diagnosis can turn life upside down for patients and their families. Providers say advancements in biomarker testing can potentially improving patient outcomes.

Lung cancer remains the leading cause of cancer deaths in Virginia, according to a new report from the American Lung Association. The 2025 “State of Lung Cancer” report for Virginia found in most ...

Biomarker testing is changing how colorectal cancer is treated, giving patients more personalized and effective care. By ...

Not available to all in New Jersey, biomarker testing is used to analyze samples of blood, tissue and other bodily fluids to identify specific genes, proteins and more that can indicate the presence ...

WASHINGTON – Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards ...